"Rhabdomyosarcoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
MeSH Number(s)
C04.557.450.590.550.660
C04.557.450.795.550.660
Below are MeSH descriptors whose meaning is more general than "Rhabdomyosarcoma".
Below are MeSH descriptors whose meaning is more specific than "Rhabdomyosarcoma".
This graph shows the total number of publications written about "Rhabdomyosarcoma" by people in Harvard Catalyst Profiles by year, and whether "Rhabdomyosarcoma" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 8 | 3 | 11 |
| 1995 | 3 | 3 | 6 |
| 1996 | 4 | 0 | 4 |
| 1997 | 2 | 3 | 5 |
| 1998 | 3 | 1 | 4 |
| 1999 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2001 | 7 | 1 | 8 |
| 2002 | 3 | 0 | 3 |
| 2003 | 0 | 2 | 2 |
| 2004 | 6 | 2 | 8 |
| 2005 | 5 | 0 | 5 |
| 2006 | 2 | 2 | 4 |
| 2007 | 4 | 5 | 9 |
| 2008 | 3 | 1 | 4 |
| 2009 | 5 | 1 | 6 |
| 2010 | 6 | 0 | 6 |
| 2011 | 5 | 2 | 7 |
| 2012 | 3 | 3 | 6 |
| 2013 | 6 | 0 | 6 |
| 2014 | 9 | 2 | 11 |
| 2015 | 4 | 4 | 8 |
| 2016 | 2 | 2 | 4 |
| 2017 | 3 | 2 | 5 |
| 2018 | 8 | 1 | 9 |
| 2019 | 7 | 0 | 7 |
| 2020 | 5 | 1 | 6 |
| 2021 | 12 | 1 | 13 |
| 2022 | 9 | 0 | 9 |
| 2023 | 4 | 0 | 4 |
| 2024 | 1 | 0 | 1 |
Below are the most recent publications written about "Rhabdomyosarcoma" by people in Profiles.
-
Germline Genetic Testing and Survival Outcomes Among Children With Rhabdomyosarcoma: A Report From the Children's Oncology Group. JAMA Netw Open. 2024 Mar 04; 7(3):e244170.
-
Common queries in managing rhabdomyosarcoma in low- and middle-income countries: An Indo-North American collaboration. Pediatr Blood Cancer. 2023 11; 70(11):e30616.
-
Long-term Urological Outcomes in Pelvic Genitourinary Rhabdomyosarcoma: A 48-Year Single-center Experience. J Urol. 2023 06; 209(6):1202-1209.
-
Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Sci Adv. 2023 02 10; 9(6):eade9238.
-
Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. J Clin Oncol. 2023 05 01; 41(13):2382-2393.
-
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma. Br J Cancer. 2022 11; 127(11):1939-1953.
-
Imaging of pediatric extremity soft tissue tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. Pediatr Blood Cancer. 2023 06; 70 Suppl 4:e29944.
-
Single-cell analysis and functional characterization uncover the stem cell hierarchies and developmental origins of rhabdomyosarcoma. Nat Cancer. 2022 08; 3(8):961-975.
-
Therapeutic targeting of ATR in alveolar rhabdomyosarcoma. Nat Commun. 2022 07 25; 13(1):4297.
-
Targeting KDM4 for treating PAX3-FOXO1-driven alveolar rhabdomyosarcoma. Sci Transl Med. 2022 07 13; 14(653):eabq2096.